Expect $125-150 mn from oral contraceptives business: Lupin
PUBLISHED ON: December 20, 2012 | Duration: 3 min, 31 sec
Lupin has received approval to launch the generic version of oral contraceptive Yasmin in the US. Ramesh Swaminathan, president of finance and planning, Lupin, explains this is a crucial product for the pharma company and could help them garner $125-150 million dollars over time. He adds that Lupin has a strong pipeline of launches for the year ahead as well.